LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways
- 1.4k Downloads
Neuroinflammation is characterized by microglial activation and the increased levels of cytokines and chemokines in the central nervous system (CNS). Recent evidence has implicated both beneficial and toxic roles of microglia when over-activated upon nerve injury or in neurodegenerative diseases, including Alzheimer’s disease (AD). The low-density lipoprotein receptor-related protein 1 (LRP1) is a major receptor for apolipoprotein E (apoE) and amyloid-β (Aβ), which play critical roles in AD pathogenesis. LRP1 regulates inflammatory responses in peripheral tissues by modulating the release of inflammatory cytokines and phagocytosis. However, the roles of LRP1 in brain innate immunity and neuroinflammation remain unclear.
In this study, we determined whether LRP1 modulates microglial activation by knocking down Lrp1 in mouse primary microglia. LRP1-related functions in microglia were also assessed in the presence of LRP1 antagonist, the receptor-associated protein (RAP). The effects on the production of inflammatory cytokines were measured by quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Potential involvement of specific signaling pathways in LRP1-regulated functions including mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) were assessed using specific inhibitors.
We found that knocking down of Lrp1 in mouse primary microglia led to the activation of both c-Jun N-terminal kinase (JNK) and NF-κB pathways with corresponding enhanced sensitivity to lipopolysaccharide (LPS) in the production of pro-inflammatory cytokines. Similar effects were observed when microglia were treated with LRP1 antagonist RAP. In addition, treatment with pro-inflammatory stimuli suppressed Lrp1 expression in microglia. Interestingly, NF-κB inhibitor not only suppressed the production of cytokines induced by the knockdown of Lrp1 but also restored the down-regulated expression of Lrp1 by LPS.
Our study uncovers that LRP1 suppresses microglial activation by modulating JNK and NF-κB signaling pathways. Given that dysregulation of LRP1 has been associated with AD pathogenesis, our work reveals a critical regulatory mechanism of microglial activation by LRP1 that could be associated with other AD-related pathways thus further nominating LRP1 as a potential disease-modifying target for the treatment of AD.
KeywordsLRP1 Microglia Inflammation JNK NF-κB RAP AD
Central nervous system
Enzyme-linked immunosorbent assay
c-Jun N-terminal kinase
Low-density lipoprotein receptor-related protein 1
Mitogen-activated protein kinase
Nonsteroidal anti-inflammatory drugs
Quantitative real-time PCR
Toll-like receptor 4
Tumor necrosis factor-α receptor 1
Tumor necrosis factor-α
Microglia are the resident innate immune cells in the central nervous system (CNS) ubiquitously distributed in the brain . When severe injury occurs, microglia change their morphology and migrate to the lesion sites. They proliferate and phagocytize dying cells and other debris and/or release cytokines to maintain the homeostasis of microenvironment impacting neuronal function and survival . However, mounting evidence has also implicated the neurotoxic roles of microglia when they are over/chronically activated in neurodegenerative diseases or under conditions of severe injury . Microglia have been widely studied for their roles in Alzheimer’s disease (AD) pathogenesis [4, 5, 6, 7]. Microglia activated by amyloid-β (Aβ) in vitro exhibit increased expression of pro-inflammatory cytokines, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), IL-6, and IL-8, that cause neuronal damage . Recent genetic studies have identified several inflammation-related genes in macrophage/microglia, including TREM2, CD33, CR1, and ABCA7, that linked to the risk of late-onset AD (LOAD) [9, 10, 11]. As aberrant activation or impaired function of the innate immune system contributes to the pathological initiation and propagation of AD [12, 13], dissecting the molecular mechanism underlying microglial activation would be beneficial for AD drug development and therapy.
The low-density lipoprotein receptor-related protein 1 (LRP1) is a type I transmembrane glycosylated protein that consists of the 515-kDa extracellular α-chain coupled to the cell surface through non-covalent interaction with the transmembrane 85-kDa β-chain [14, 15]. In the CNS, LRP1 is ubiquitously expressed and serves as a critical transport receptor as well as a modulator of several distinct signaling pathways in the vasculature [16, 17], blood brain barrier , neurons , astrocytes , and microglia . LRP1 regulates the metabolism of over 40 ligands, including Aβ and apolipoprotein E (apoE) as well as proteases and growth factors implicated in inflammation [14, 22, 23]. Conditional deletion of the mouse Lrp1 gene in forebrain neurons leads to an increase in glial activation and elevated production of pro-inflammatory cytokines . Deficiency of LRP1 in macrophage leads to down-regulation of anti-inflammatory markers while enhancing the macrophage response to pro-inflammatory stimuli . In the peripheral nervous system, soluble LRP1 (sLRP1), which consists of the entire LRP1 α-chain and part of the β-chain ectodomain, can bind directly to Schwann cell surfaces and inhibit the cellular response to TNF-α . It has also been demonstrated that LRP1 intracellular domain (LICD) suppresses lipopolysaccharide (LPS)-induced inflammatory responses by binding to the interferon-γ promoter in macrophage . In addition, activation of the LDL receptor family members has been reported to modulate glial inflammation by modulating mitogen-activated protein kinase . However, the molecular mechanism underlying LRP1-mediated inflammation in CNS remains unclear. In this study, we investigated whether and how LRP1 mediates microglial activation and further unraveled the signaling pathways underlying LRP1 functions in microglia.
Antibodies and chemical reagents
The following antibodies were used in this study: anti-MAP2 (Cell Signaling), anti-GFAP (Abcam), anti-Iba-1 (Wako), anti-apoE (Meridian Life Science), anti-Phospho-SAPK/JNK (Thr183/Tyr185), anti-JNK, anti-c-Jun, anti-Phospho-c-Jun (Ser73), anti-NF-κB p65, anti-Phospho-NF-κB p65 (Ser536), anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), anti-p44/42 MAPK (Erk1/2), anti-p38 MAPK, anti-Phospho-p38 MAPK, anti-Phospho-IκBα (Ser32), anti-IκBα, and anti-β-actin (Cell Signaling). Rabbit polyclonal anti-LRP1 was produced in our laboratory . LPS, mouse TNF-α, NF-κB inhibitor (BAY 11-7082), and JNK inhibitor (SP600125) were purchased from Sigma-Aldrich.
Oligomeric Aβ42 was obtained from the Proteomics Core at the Mayo Clinic and prepared as previously described . Briefly, aliquots of 100 μM Aβ monomer purified by size exclusion chromatography were incubated overnight at room temperature in 50 mM NaCl and 4 mM SDS. To remove SDS and reduce salt concentration, the sample was dialyzed against 20 mM sodium phosphate buffer at pH 7.0 (NaP) for 48–72 h and then against 10 mM NaP. Sample quality was monitored and confirmed at each step of the preparation by circular dichroism (CD) and thioflavin T fluorescence. Residual or unconverted monomer was removed by filtering the dialyzed oligomer with an Amicon Ultra 4 centrifugal concentration/filtration device with a MW cutoff of 50 kDa.
Expression and purification of recombinant RAP
Recombinant receptor-associated protein (RAP) was purified as described previously  with minor modifications. Briefly, DH5α bacteria harboring the GST-RAP protein were grown at 37 °C to an O.D. of 0.7 at 600 nm. Expression was induced by the addition of isopropylthio-β-d-galactoside to a final concentration of 0.01%, and the cultures were grown for another 4 h at 30 °C. Bacteria were harvested by centrifugation at 4 °C and resuspended in PBS containing 1% (v/v) Triton X-100, 1 mM PMSF, complete proteinase inhibitor, 1 mM EDTA. Bacteria were sonicated and centrifuged at 26,000g for 30 min at 4 °C. The supernatant was mixed with glutathione beads at 4 °C, washed in PBS, and thereafter with 50 mM Tris-HCl at pH 8.0. Bound GST-RAP protein was eluted with 50 mM Tris-HCl containing 20 mM reduced glutathione at pH 8.0. The eluate was dialyzed against 50 mM Tris-HCl at pH 8.0, and the fusion protein was cleaved with thrombin in 50 mM Tris-HCl, 150 mM NaCl, and 2.5 mM CaCl2 at pH 8.0. The free RAP was removed from the GST via heparin sepharose column. Following washes with 20 mM Tris-HCl at pH 7.4, RAP was eluted from the column with 20 mM Tris-HCl, 2 M NaCl at pH 7.4, and was then dialyzed against 50 mM Tris-HCl at pH 7.4. To remove the potential bacterial endotoxin, purified RAP was incubated with endotoxin removal resin (Thermo Fisher) according to the manufacturer’s instruction. Before treatment, RAP stock solutions were filtered with 0.22 μm sterile syringe filters.
Mouse primary cell culture
Primary microglia were prepared as previously described [32, 33] with minor modifications. Briefly, mixed glial cells from C57BL/6J neonatal mice at postnatal day 1 to day 3 (P1-P3) were cultured in DMEM (Gibco) supplemented with 10% heat-inactivated FBS (Moregate) and 1% penicillin streptomycin solution (100 U/mL penicillin, and 100 μg/mL streptomycin, Invitrogen). The medium was changed 3 days later with fresh DMEM medium containing 10% FBS, 1% penicillin streptomycin, and 25 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D Systems). Primary microglia were harvested by shaking after 10–12 days in culture and once a week thereafter for up to three times. The purity of the isolated microglia was >95% as determined by flow cytometry analysis with antibody against CD11b (BD Biosciences).
Lrp1 knockdown by small-interfering RNA
Mouse Lrp1-specific siRNAs and non-targeting control were purchased from Dharmacon Research. The siRNA sequences for mouse Lrp1 were as followed: Lrp1 siRNA1: 5′-GGAGUCACUUACAUCAAUAUU-3′; Lrp1 siRNA2: 5′-GCAGCGAGCCAACAAG UAU-3′. siRNAs were transfected into primary microglia using Basic Nucleofector™ Kit for Primary Mammalian Glial Cells (VPI-1006, Lonza) according to the manufacturer’s specifications. Each electroporation reaction contained 6 × 106 cells and 300 nM siRNA. Cells were further cultured for 48 h before using in experiments and analysis.
Primary microglia treatment
Primary microglia from C57BL/6J neonatal mice was cultured in the medium without GM-CSF for 24 h. Cells were then transferred to serum-free medium for 30 min and then treated with RAP (25 or 50 nM) for 4 h (for quantitative real-time PC (qRT-PCR)) or 30 min (for Western blotting). Cells were treated with LPS (100 ng/ml) as a positive control. For the treatment with inflammatory stimuli, primary microglia was cultured in the medium without GM-CSF for 24 h. Cells were further transferred to serum-free medium for 30 min and then cultured in the presence of either PBS (control), LPS (100 ng/ml), mouse TNF-α (100 ng/ml), or oligomeric Aβ (10 μM) for another 24 h (for qRT-PCR and Western blotting).
Cells were harvested and homogenized in Nonidet P-40 lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride supplemented with protease inhibitors cocktail). The samples were centrifuged at 12,000×g for 15 min at 4 °C. The supernatant was collected, and total protein levels were measured by the micro-BCA protein assay kit (Thermo Fisher Scientific). Equal amounts of total proteins were separated by SDS-PAGE and transferred to PVDF membrane (Millipore). The membranes were blocked with 5% nonfat milk in TBST (Tris-buffered saline, 20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20, pH 7.6) and probed with primary antibodies, followed by treatment with HRP-linked secondary antibodies and ECL Western blotting detection reagents. The intensity of immune-reactive bands was quantified using ImageJ software.
Quantitative real-time PCR
Total RNA was isolated from cells using TRIzol reagent (Invitrogen) and then dissolved in nuclease-free water and stored at −80 °C. Reverse transcription was performed using a ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO) according to the manufacturer’s protocol. Quantitative real-time PCR (qRT-PCR) was performed using the FastStart Universal SYBR Green Master (Roche) on the 7500 fast real-time PCR platform (ABI). Each reaction was run in triplicate, and the real-time value for each sample was averaged and compared using the CT method, where the amount of target RNA (2−ΔΔCT) was obtained by normalization to an endogenous reference (β-actin) and relative to a calibrator. Gene expression was considered undetectable if the Ct value was greater than 33 cycles. The primer sequences for Lrp1, Il-1β, Tnf-α, Il-10, Apoe, and β-actin were as follows: Lrp1-forward: 5′-ACTATGGATGCCCCTAAAACTTG-3′; Lrp1-reverse: 5′-GCAATCTCTTTCACCGTCACA-3′; Il-1β-forward: 5′-GCAACTGT TCCTGAACTCAACT-3′; Il-1β-reverse: 5′-ATCTTTTGGGGTCCGTCAACT-3′; Tnf-α-forward: 5′-CCCTCACACTCAGATCATCTTCT-3′; Tnf-α-reverse: 5′-GCTACGAC GTGGGCTACAG-3′; Il-10-forward: 5′-GCTCTTACTGACTGGCATGAG-3′; Il-10-reverse: 5′-CGCAGCTCTAGGAGCATGTG-3′; Apoe-forward: 5′-CTGACAGGATGC CTAGCCG-3′; Apoe-reverse: 5′-CGCAGGTAATCCCAGAAGC-3′; β-actin-forward: 5′-AGTGTGACGTTGACATCCGTA-3′; β-actin-reverse: 5′-GCCAGAGCAGTAATC TCCTTC.
IL-1β and TNF-α in conditioned media were measured using the antibodies and reference standards contained in R&D Systems DuoSet enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s protocol.
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software). Data were presented as average ± SEM. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc analysis. All experiments were repeated with a minimum of three times. A p value of <0.05 was considered as statistically significant.
Knockdown of Lrp1 exacerbates LPS-stimulated pro-inflammatory cytokine production
JNK and NF-κB pathways are activated in Lrp1-knockdown primary microglia
LRP1 antagonist RAP regulates inflammation in microglia by modulating JNK and NF-κB pathways
JNK and NF-κB inhibitors eliminate the hypersensitivity of LRP1-knocked down microglia to LPS
LRP1 expression in primary microglia is down-regulated by pro-inflammatory stimuli
NF-κB inhibitor restores LRP1 expression down-regulated by LPS
Neuroinflammation induced by microglial activation is an important pathological feature and an early event in the pathogenesis of AD. The predominant microglia phenotype is termed M1 state associated with a chronic neuroinflammatory environment accompanied by the increased and sustained release of pro-inflammatory mediators that modify AD progression [8, 43, 44, 45]. The important role of neuroinflammation in AD is also supported by the identification of AD risk genes including TREM2 and CD33 that predominantly expressed in microglia [10, 11, 46]. LRP1 is a widely studied receptor due to its involvement in multiple pathways in AD pathogenesis including modulation of Aβ clearance, lipid transport, and synaptic functions [22, 29, 47]. As the major immune cell type in the CNS, microglia have been reported to express higher levels of LRP1 transcript in the brain tissues of wild-type mice . Several studies revealed that LRP1 might regulate microglial functions in CNS. The uptake of Aβ-coated yeast particles in microglia was suppressed by the presence of LRP1 ligands, indicating that LRP1 might regulate Aβ phagocytosis in microglia . LRP1 was also shown to mediate phagocytosis of apoptotic cells by binding to cell surface calreticulin . In addition, recent work by Chuang et al. demonstrated that in the brains of microglial Lrp1 conditional knockout mice, microglia adopt a pro-inflammatory phenotype characterized by amoeboid morphology, indicating that LRP1 may regulate microglial activation in vivo. Of note, their work also suggests that ablation of LRP1 in microglia, not in macrophage, had a significant impact on the disease severity of multiple sclerosis . However, the regulation and function of LRP1 as well as related signaling pathways in microglia remain to be elucidated. In the present study, we found that down-regulating LRP1 expression in microglia results in an increase of pro-inflammation cytokines. We also demonstrated that suppression of LRP1 expression or function in microglia leads to the activation of both JNK and NF-κB signaling pathways, suggesting that LRP1 in microglia directly regulates specific signaling pathways critical for inflammatory responses.
Previous studies have shown that LRP1 can directly regulate cellular signaling pathways via multiple mechanisms . Here, we found that there was an aberrant JNK activation in LRP1-deficient microglia. Interestingly, the cytoplasmic domain of LRP1 (LRP1-ICD) binds JNK-interacting proteins (JIP-1 and JIP-2), which have been identified as modulators of the JNK signal transduction pathway . It has also been demonstrated that overexpression of LRP1-ICD selectively prevents the activated JNK from translocating into the nucleus and, subsequently, nuclear transactivation of the JNK-dependent transcription factors, c-Jun and/or Elk-1 . It is possible that LRP1 sequesters JNK by forming a complex with JIP, through which it regulates the JNK activation in microglia.
Consistent with the study by Chuang et al. in macrophage , our current study also found that LRP1 down-regulation in primary microglia not only leads to NF-κB activation in the absence of inflammatory stimuli but also enhances the LPS-induced NF-κB activity. Gaultier et al. has described a potential mechanism through which LRP1 may suppress NF-κB activation in mouse macrophage. Loss of LRP1 leads to increased surface expression of TNF-α receptor 1 (TNFR1) thus sensitizing the cell to the inflammatory signaling initiated by TNF-α. This results in an increased activation of NF-κB via phosphorylation and degradation of its inhibitory binding protein IκB . Further studies are needed to understand the mechanism underlying LRP1-mediated NF-κB activation in microglia.
LRP1 regulates the metabolism of over 40 extracellular ligands; however, existing microglial Lrp1 conditional knockout mouse model does not address the role of LRP1 as a receptor for diverse ligands . Here we have explored the role of LRP1 antagonist RAP in microglial activation. We observed that RAP promotes the expression of pro-inflammatory cytokines and triggers JNK and NF-κB activation in microglia. Although the specific LRP1 ligands that mediate the inflammatory responses remain to be identified, our results suggest that RAP may inhibit the binding of ligands to LRP1 and therefore trigger microglial activation. Indeed, a previous study has shown that the LRP1 agonist attenuated the expression of pro-inflammatory mediators even in the presence of LPS, while the antagonist and LRP1 antibody that block its function had an opposite effect in macrophage . Identifying specific LRP1 ligands that are involved in the regulation of microglial activation might provide a novel target for AD therapy.
LRP1 is highly expressed in the brain under normal physiological conditions, while it has been reported that the brains of AD patients had significantly lower LRP1 levels than those of age-matched controls. Moreover, higher LRP1 levels significantly correlate with later ages at onset of AD, while age and LRP1 expression in normal individuals appear to be inversely correlated . To our knowledge, there are few reports regarding LRP1 function or the expression regulation of LRP1 in microglia during AD progression. Others and us have found that various stimuli (including LPS, TNF-α, and oligomeric Aβ42) down-regulate the microglial expression of LRP1 and apoE but increase the expression of pro-inflammatory cytokines, indicating that the expression of LRP1 and its ligands is essential for modulating glial activation [58, 59]. Indeed, it has been shown that LRP1 ligand apoE modulates microglial inflammation through LRP1 . Together, LRP1 expression may be either down-regulated in glial cells due to neuroinflammation or suppressed in neurons due to post-synaptic damages in AD. Further studies are needed to clarify the temporal and spatial regulation of LRP1 expression during AD progression.
Since both JNK and NF-κB pathways are responsible for microglial activation in LRP1-deficient microglia or in the presence of LRP1 antagonist, we further investigated whether blocking these pathways could suppress the production of pro-inflammatory cytokines induced by LRP1 down-regulation in microglia. We found that JNK inhibitor (SP600125) blocks the increase of IL-1β in Lrp1-KD microglia; however, it failed to restore the level of TNF-α. Interestingly, the higher levels of pro-inflammatory cytokines seen in Lrp1-KD microglia were significantly suppressed by NF-κB inhibitor (BAY11-7082). Our results further showed that NF-κB inhibitor rescues LPS down-regulated LRP1 expression. As JNK pathway was also repressed by BAY11-7082, this inhibitor might block both JNK and NF-κB pathways. Thus, the precise mechanism requires further investigation using molecular and genetic approaches in addition to the pharmacological inhibitors used in this study.
As central signaling pathways of neuroinflammation, the activation of JNK and NF-κB is involved in several pathophysiological processes of AD. In the brain of AD patients, activated JNK and NF-κB were found predominantly in neurons and glial cells in areas surrounding Aβ plaque [60, 61, 62, 63, 64, 65]. Several studies have shown that JNK and NF-κB inhibitors are effective in slowing down disease progression. Some nonsteroidal anti-inflammatory drugs (NSAIDs) have a direct effect on NF-κB activity, which also leads to a decrease in Aβ production. Flurbiprofen and indomethacin, which target NF-κB, have been shown to effectively reduce the amyloid plaque load in AD mouse models [66, 67]. JNK inhibition could promote the expression of apoE in microglia to reduce inflammation . Moreover, inhibition of JNK activation by chronic treatment of SP600125 markedly reduces multiple pathological features and ameliorates cognitive deficits in APPswe/PS1dE9 mice . Based on our current findings, BAY11-7082 may be a promising anti-inflammatory inhibitor targeting LRP1 for the treatment of AD.
In summary, we demonstrate that LRP1 suppresses microglial activation by modulating JNK and NF-κB signaling pathways. Down-regulation of LRP1 levels and the increased pro-inflammatory signaling may result in a vicious cycle, in which the two events synergistically promote microglial activation. Restoration of LRP1 expression in microglia may serve as a novel therapeutic approach to combat microglial dysfunction associated with chronic inflammation in neurodegenerative diseases including AD. Further studies should be carried out in AD mouse models deficient of microglial LRP1 to better understand the specific functions of LRP1 in microglia in the presence of AD-related pathologies.
Research by the authors was supported by NIH grants R01AG035355, R01AG027924, R01AG046205, P01AG030128, and P01NS074969 (to G.B.), a grant from the Cure Alzheimer’s Fundation (to G.B.), grants from the National Natural Science Foundation of China 81370459, 31400914 (to X.C.), and U1505227 (to G.B.), a grant from the Fundamental Research Funds for the Central Universities (20720150051, to X.C.), and a grant from the Guangdong Natural Science Foundation (2016A030306005, to X.C.).
Availability of data and materials
The data used in this article are available upon request.
LY, C-CL, TK, XC, and GB designed the research; LY, HZ, AY, LJ, DW, and DC performed the research; LY and C-CL analyzed data; LY, C-CL, XC, and GB wrote the paper. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
All animal experiments were conducted in compliance with the protocols of the Institutional Animal Care and Use Committee at Mayo Clinic and Xiamen University.
- 6.Dickens AM, Vainio S, Marjamaki P, Johansson J, Lehtiniemi P, Rokka J, Rinne J, Solin O, Haaparanta-Solin M, Jones PA, et al. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med. 2014;55:466–72.CrossRefPubMedGoogle Scholar
- 19.May P, Rohlmann A, Bock HH, Zurhove K, Marth JD, Schomburg ED, Noebels JL, Beffert U, Sweatt JD, Weeber EJ, Herz J. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol. 2004;24:8872–83.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–34.CrossRefPubMedGoogle Scholar
- 55.Gaultier A, Arandjelovic S, Niessen S, Overton CD, Linton MF, Fazio S, Campana WM, Cravatt 3rd BF, Gonias SL. Regulation of tumor necrosis factor receptor-1 and the IKK-NF-kappaB pathway by LDL receptor-related protein explains the antiinflammatory activity of this receptor. Blood. 2008;111:5316–25.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH. Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000;106:1159–66.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:2642–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 67.Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM, Pratico D. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer’s disease. Am J Pathol. 2004;165:2197–206.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.